http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국인 원발성 사구체신염에서의 IL-1β, IL-1Ra, TNF-α 유전자 다형성에 관한 연구
박미나 ( Mi Na Park ),강양일 ( Yang Il Kang ),이상열 ( Sang Youl Rhee ),정래익 ( Lae Ik Jeong ),나승연 ( Seung Yeon Na ),정경환 ( Kyung Hwan Jeong ),이상호 ( Sang Ho Lee ),이태원 ( Tae Won LEE ),임천규 ( Chun Gyoo Ihm ) 대한신장학회 2006 Kidney Research and Clinical Practice Vol.25 No.2
만성 폐쇄성 폐질환 환자에서 tiotropium 흡입제의 효과
강양일 ( Yang Il Kang ),노태준 ( Tae Jun Noh ),최혜숙 ( Hye Sook Choi ),최천웅 ( Cheon Woong Choi ),박명재 ( Myung Jae Park ),강홍모 ( Hong Mo Kang ),유지홍 ( Jee Hong Yoo ) 대한내과학회 2007 대한내과학회지 Vol.73 No.2
Background: Tiotropium is a long acting anticholinergic bronchodilator and it reduces exacerbations and improves the quality of life of patients with stable chronic obstructive pulmonary disease (COPD). The purpose of this study was to evaluate the effect of tiotropium on dyspnea, the quality of life and the pulmonary function in patients with COPD. Methods: Between April 2005 and April 2006, the patients with moderate to severe COPD, as based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and who needed to use long-acting bronchodilator were enrolled in this study. They inhaled tiotropium as a dry powder capsule, 18 μg once daily for six months, with using the Handihaler(R) device. The lung function tests, including lung volume, the St. George`s respiratory questionnaire and the MRC dyspnea scale, was measured at baseline and after 6 months treatment with tiotropium. Results: 21 patients with COPD were enrolled. The mean age of the patients was 69 years and the mean baseline FEV1 was 1.0 L (40% predicted). Compared with the baseline, tiotropium produced significant improvement of the FEV1 (1.0±0.2 L vs. 1.1±0.3 L, respectively, p=0.013), IC (1.65±0.3 L vs. 1.7±0.3 L, respectively, p=0.037), the RV (4.0±0.7 L vs. 3.8±0.4, respectively, p=0.003), the SGRQ score (48.7±10 vs. 41.3±10.4, respectively, p<0.001), and the MRC dyspnea scale (3.4±0.6 vs. 3.0±0.8, respectively, p=0.009) after 6 months treatment. The dyspnea scale was associated with physical activity, the impact on life, the inspiratory capacity and the residual volume rather than the symptom score or FEV1. The treatment was well tolerated. Conclusions: Treatment with tiotropium once daily for 6 months improved lung functions, the health related quality of life and dyspnea.(Korean J Med 73:159-168, 2007)